Side-by-side · Research reference

BPC-157vsHGH 191AA

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BFDA-ApprovedHUMAN-REVIEWED0/75 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

01Mechanism of Action

Parameter

BPC-157

HGH 191AA

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Feedback intact?

No known endogenous receptor; mechanism still under investigation

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Antibody development

—

Rare — <2% develop binding antibodies, typically non-neutralizing

02Dosage Protocols

Parameter

BPC-157

HGH 191AA

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

FDA-approved / decades of RCT data

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

Years (children until epiphyseal closure); indefinite (adult GHD)

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Pediatric GHD

—

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

Adult GHD

—

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

Turner syndrome

—

0.045–0.050 mg/kg/day SQ

Idiopathic short stature

—

0.037 mg/kg/day SQ

AIDS wasting

—

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

Monitoring

—

IGF-1, glucose, thyroid function, bone age (children)

03Metabolic / Fat Loss Evidence

Parameter

BPC-157

HGH 191AA

Primary fat target

—

Visceral and subcutaneous adipose tissue

Mechanism

—

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Effect on lean mass

—

Significant lean mass increase (protein synthesis, nitrogen retention)

Insulin sensitivity

—

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

IGF-1 elevation

—

Dose-dependent, significant — primary anabolic mediator

Glucose metabolism

—

Hyperglycemia risk, especially high doses (AIDS wasting)

Body composition

—

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

Clinical context

—

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

04Side Effects & Safety

Parameter

BPC-157

HGH 191AA

Injection site reaction

Mild irritation (anecdotal)

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

Antibody formation

No data (no long-term human trials)

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

Glucose intolerance

—

Hyperglycemia, new-onset diabetes (anti-insulin effect)

Intracranial hypertension

—

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

Slipped capital femoral epiphysis

—

SCFE risk in children — limp, hip/knee pain (requires surgery)

Scoliosis progression

—

Rapid growth may unmask/progress scoliosis (monitor spine in children)

Hypothyroidism

—

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

Pancreatitis

—

Rare. Higher risk in children with certain syndromes (Prader-Willi).

Gynecomastia

—

Adolescent males (physiological during puberty, may be exacerbated)

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

05Administration Protocol

Parameter

BPC-157

HGH 191AA

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

6. Monitoring

—

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms